Key Highlights

  • Net loss for the third quarter was USD 73.6 million, or USD 0.73 per share, compared with USD 42.2 million, or USD 0.49 per share, in the same period a year earlier.
  • Research and development expense rose to USD 67.6 million from USD 40.0 million, while general and administrative expense increased to USD 9.9 million from USD 5.9 million.
  • Cash, cash equivalents and marketable securities totaled USD 413.8 million at September 30, 2026, and management expects that to fund the current operating plan for at least 12 months.
  • Top-line results from the Phase 3 OPERA-01 trial of palazestrant are expected in the first quarter of 2027, with a new drug application planned for 2027.

Spending Ramps Ahead of the OPERA-01 Readout

Olema Pharmaceuticals (NASDAQ:OLMA) filed its Quarterly Report on November 10, 2026, covering the period ended September 30, 2026. The company has no Revenue from product sales, so the loss tracks spending, and it reported no product candidates approved for sale. Total operating expenses were USD 77.5 million against USD 45.9 million a year earlier, and interest income of USD 4.1 million partly offset the loss. For nine months, net loss was USD 189.9 million, or USD 1.89 a share, versus USD 116.4 million, or USD 1.36. Stock-based compensation was USD 35.1 million of the nine-month total, up from USD 13.3 million.

Palazestrant, OP-3136 and the Catalyst Calendar

Olema is a clinical-stage company developing targeted therapies for breast cancer. Its lead candidate, palazestrant, is an oral estrogen receptor antagonist and degrader being tested in ER-positive, HER2-negative metastatic breast cancer. Enrollment is complete in OPERA-01, the monotherapy Phase 3 trial, and the company anticipates top-line results in the first quarter of 2027 and potential FDA approval in 2028 if successful. The company also expects to present early combination data for palazestrant and for its KAT6 inhibitor OP-3136 at the San Antonio Breast Cancer Symposium in December 2026. A Bayer combination arm for OP-3136 in metastatic castration-resistant prostate cancer, planned for about 36 patients, is expected to start in the fourth quarter.

Cash Burn, Equity Sales and Going-Concern Language

Net cash used in Operating Activities was USD 139.0 million for nine months versus USD 108.4 million. Financing brought in USD 47.2 million, mainly USD 41.9 million of net proceeds from at-the-market share sales. Cash and securities fell from about USD 505.4 million at year-end (calculated from the balance sheet) to USD 413.8 million. The filing says the company has incurred losses since inception, may be unable to continue as a Going Concern over the long term, and will need substantial additional capital. Selling shares to raise it dilutes existing holders, and a trial miss would hit a company that depends on one lead candidate.

Where Things Stand

Because spending is climbing as the lead trial finishes. Olema Pharmaceuticals (NASDAQ:OLMA) lost USD 73.6 million in the quarter, driven by Research and Development of USD 67.6 million, and it has no product revenue. The Balance Sheet of USD 413.8 million supports at least 12 months of the current plan, according to management, but the filing flags long-term going-concern risk. The next markers are the OPERA-01 top-line results in the first quarter of 2027, December symposium data and any further equity raises.